InCarda Therapeutics, Inc.
Pioneering development of transformative therapies that patients can self-administer to treat acute cardiovascular conditions in Afib and MI
InCarda develops novel inhaled cardio therapies for acute cardiac conditions. Inhalation permits early treatment by delivering a bolus drug directly to the regions in the heart where stimuli for acute cardiac conditions arise. InCarda's lead product is intended to rapidly & safely convert Afib to normal rhythm in an outpatient setting. The Heart Attack Inhaler is to intended save lives of MI patients. Both indications have large worldwide markets